Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.

Company profile
Ticker
SYK
Exchange
Website
CEO
Kevin Lobo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
2Hip Holdings SAS • Aimago SA • Alcott Indemnity Company • Arrinex, Inc. • Berchtold + Fritz GmbH • Berchtold Corporation • Berchtold GmbH & Co. KG • Berchtold Holding Switzerland GmbH • BioMimetic Therapeutics USA, Inc. • BioMimetic Therapeutics, LLC ...
IRS number
381239739
SYK stock data
Analyst ratings and price targets
Latest filings (excl ownership)
SD
Conflict minerals disclosure
26 May 23
8-K
Submission of Matters to a Vote of Security Holders
16 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Stryker Reports First Quarter 2023 Operating Results
1 May 23
UPLOAD
Letter from SEC
27 Apr 23
CORRESP
Correspondence with SEC
25 Apr 23
UPLOAD
Letter from SEC
11 Apr 23
CORRESP
Correspondence with SEC
30 Mar 23
DEFA14A
Additional proxy soliciting materials
28 Mar 23
DEF 14A
Definitive proxy
28 Mar 23
Transcripts
SYK
Earnings call transcript
2022 Q4
31 Jan 23
SYK
Earnings call transcript
2022 Q3
1 Nov 22
SYK
Earnings call transcript
2022 Q2
27 Jul 22
SYK
Earnings call transcript
2022 Q1
29 Apr 22
SYK
Earnings call transcript
2021 Q4
28 Jan 22
SYK
Earnings call transcript
2021 Q3
29 Oct 21
SYK
Earnings call transcript
2021 Q2
28 Jul 21
SYK
Earnings call transcript
2021 Q1
28 Apr 21
SYK
Earnings call transcript
2020 Q4
28 Jan 21
SYK
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
4
Srikant M. Datar
19 May 23
144
Notice of proposed sale of securities
18 May 23
4
Andrew K Silvernail
12 May 23
4
Rajeev Suri
12 May 23
4
RONDA E STRYKER
12 May 23
4
Tatum Lisa M Skeete
12 May 23
4
Sherilyn S McCoy
12 May 23
4
Allan C. Golston
12 May 23
4
Srikant M. Datar
12 May 23
4
Giovanni Caforio
12 May 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.67 bn | 1.67 bn | 1.67 bn | 1.67 bn | 1.67 bn | 1.67 bn |
Cash burn (monthly) | 57.67 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 110.36 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 1.56 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 27.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
77.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1648 |
Opened positions | 160 |
Closed positions | 123 |
Increased positions | 547 |
Reduced positions | 641 |
13F shares | Current |
---|---|
Total value | 83.65 tn |
Total shares | 294.83 mm |
Total puts | 910.51 k |
Total calls | 1.54 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 30.30 mm | $8.65 tn |
BLK Blackrock | 24.67 mm | $7.04 tn |
Greenleaf Trust | 19.30 mm | $5.51 tn |
Wellington Management | 16.16 mm | $4.61 tn |
Capital Research Global Investors | 16.03 mm | $4.58 tn |
T. Rowe Price | 14.32 mm | $4.08 tn |
STT State Street | 14.05 mm | $4.02 tn |
BK Bank Of New York Mellon | 6.68 mm | $1.91 tn |
FMR | 6.01 mm | $1.72 tn |
Geode Capital Management | 5.95 mm | $1.70 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 May 23 | Srikant M. Datar | Common Stock | Sell | Dispose S | No | No | 286 | 1,000 | 286.00 k | 5,967 |
10 May 23 | Brainerd Mary K | Common Stock | Grant | Acquire A | No | No | 0 | 705 | 0.00 | 5,815 |
10 May 23 | Caforio Giovanni | Common Stock | Grant | Acquire A | No | No | 0 | 705 | 0.00 | 2,555 |
10 May 23 | Srikant M. Datar | Common Stock | Grant | Acquire A | No | No | 0 | 705 | 0.00 | 6,967 |
10 May 23 | Golston Allan C. | Common Stock | Grant | Acquire A | No | No | 0 | 705 | 0.00 | 14,242 |
News
Analyst Ratings for Stryker
25 May 23
Argus Research Maintains Buy on Stryker, Raises Price Target to $310
25 May 23
Meta Platforms, JPMorgan And 2 Other Stocks Insiders Are Selling
22 May 23
$100 Invested In Stryker 10 Years Ago Would Be Worth This Much Today
11 May 23
10 Health Care Stocks With Whale Alerts In Today's Session
8 May 23
Press releases
Surgeons Successfully Complete First Surgical Cases Using Stryker's Q Guidance System with Cranial Guidance Software
24 May 23
Stryker declares a $0.75 per share quarterly dividend
10 May 23
Stryker completes acquisition of Cerus Endovascular
2 May 23
Stryker reports first quarter 2023 operating results
1 May 23
Pressure Ulcers Treatment Market Size US$ 6.9 Billion by 2028 With Growth Rate (CAGR) 5.18% | IMARC Group
27 Apr 23